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The formation and dissolution of blood clots is both a biochemical and a biomechanical process. While much of the chemistry has
beenworked out for both processes, the influence of biophysical properties is less well understood.This review considers the impact
of several structural and mechanical parameters on lytic rates of fibrin fibers. The influences of fiber and network architecture,
fiber strain, FXIIIa cross-linking, and particle transport phenomena will be assessed. The importance of the mechanical aspects of
fibrinolysis is emphasized, and future research avenues are discussed.
1. Introduction
Coagulation and fibrinolysis serve as complementary but
competingmechanisms during the process of wound healing.
Activation of the coagulation cascade due to vascular injury
results in the formation of a fibrin network, which serves to
seal the injury. Formation of fibrin activates the fibrinolytic
system, a set of enzymes, and inhibitors whose function is to
regulate the breakdown of the fibrin network. These systems
have been studied for over sixty years, and many of the main
pathways have been studied and identified.
In the past decade the mechanical properties of fibrin
have received renewed interest with the revelation that fibrin
is among the most elastic and extensible biomaterials [1,
2], and recent studies have begun to explore the direct
correlation between fibrin extension and fibrinolytic rates
[3]. This review will focus on the intersection of fibrinolysis
and fibrin’s biophysical properties, with an emphasis on basic
scientific discoveries and not clinical treatment strategies.
However, it is expected that a deeper understanding of how
themechanical properties of fibrinmediate fibrinolysis could
have clinical relevance. Lytic strategies for treating acute
myocardial infarctions often see recanalization rates of only
80%–90%, while the mechanical breakdown of blood clots
often achieves higher patency [4]. This suggests the need for
a further examination of the fibrinolytic determinants and
highlights the importance of understanding fibrinolysis in
light of fibrin’s biophysical characteristics. This review is not
exhaustive for all aspects of fibrinolysis but emphasizes major
events, and as with any review there are many papers that
could have been cited that were not and many topics that
could have been covered in greater detail that only receive a
surface treatment; the author apologizes for any oversites in
these cases.
2. Fibrinogen and Fibrin
2.1. Structure and Polymerization. Human fibrinogen is a
soluble, 46 nm long, 340 kDa glycoprotein and is the third
most prevalent protein found in blood plasma, circulating
at 6–12 𝜇M [5]. It is assembled as a homodimer, with each
subunit consisting of three polypeptide chains (called A𝛼,
B𝛽, and 𝛾), having 610, 461, and 411 amino acid residues,
respectively [6].Within the fibrinogenmolecule, all six chains
are oriented so that their N-termini are located in the central
region and held together by five disulfide bonds [6, 7]. From
both sides of the central nodule, the three chains extend into
𝛼-helices that form a triple coiled coil structure, terminating
with a series of disulfide bonds, linking the three chains
again at the C-terminus of the coiled coil [7, 8]. Beyond this
disulfide linkage, the C-terminal segments of the B𝛽 and
𝛾 chains fold independently to form the compact, globular
𝛽- and 𝛾-nodules (see Figures 1(a) and 1(b)) [8]. The C-
terminal segment of the A𝛼 chain (called the 𝛼C region) is
different, briefly folding back to form a fourth 𝛼-helix, before
extending into a primarily unstructured region, which has
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Figure 1:The fibrin molecule and polymerization into fibers. (a) Crystallography-based fibrin molecule: the fibrin molecule structure shown
was created using crystal structure 3GHG [9], combined with discrete molecular dynamics methods to fill in amino acids 𝛼17–26, 𝛼201–610,
and 𝛽15–57 [15], which were missing in the crystal structure. The 𝛼 chain is shown in green, 𝛽 chain in red, and 𝛾 chain in blue; disulfide
bonds are emphasized as yellow spheres.The 𝛼C region was built from homologymodeling andmolecular dynamics methods as described in
[15]. Fibrin degradation fragments D and E are highlighted. Fragment X is formed from plasmin cleavage of the 𝛼C region. (b) Cartoon fibrin
molecule: upon thrombin cleavage of FpA and FpB, knob A and knob B are exposed to bind the respective hole a and hole b. Cartoon model
highlights these interactions and draws structural correlations between the crystal structure and the cartoon (c) Polymerization model for a
protofibril: during polymerization, a half-staggered protofibril is formed as the knobs in the central region of one molecule bind to the holes
in the distal region of two opposite molecules. Knob B has been implicated in the lateral aggregation of protofibrils and could potentially bind
to holes in adjacent protofibrils (not shown).
been uncrystallizable [9]. The 𝛼C region is often grouped
into two subregions: the 𝛼C connector (221–391) and the
𝛼C domain (392–610) [10, 11]. The 𝛼C connector region is
thought to be unstructured and consists of 10, 13-amino
acid repeats [10] in humans, while electron microscopy and
circular dichroism (CD) studies indicate that the 𝛼C domain
contains a folded structure [12, 13]. CD and NMR studies
have further clarified the 𝛼C domain structure, finding that
the lone disulfide bond in the 𝛼C domain stabilizes a double
𝛽 hairpin structure in residues 𝛼392–503, while a second,
uncharacterized, structured region also exists in 𝛼504–610
[13, 14]. A similar, but not identical, 𝛽-sheet structure was
found for the 𝛼C domain using homology modeling and
molecular dynamics simulations [15]. In fibrinogen, it is
thought that the 𝛼C domains interact with each other and the
FpB in the central region [16].
Fibrinogen is converted into insoluble fibrin when the
enzyme thrombin cleaves the R16-G17 bond in each A𝛼
chain and the R14-G15 bond in each B𝛽 chain. Release of
these peptides (fibrinopeptides A and B, or FpA and FpB)
BioMed Research International 3
exposes the “A” and “B” knobs, which bind to corresponding
“a” and “b” holes in the 𝛽- and 𝛾-nodules, allowing fibrin
fiber polymerization (see Figures 1(a) and 1(b)). FpA is
cleaved more rapidly than FpB, and the “A:a” knob:hole
interaction is the primary mediator of polymerization [11].
Cleavage of FpB may release the 𝛼C domains from the fibrin
molecule, allowing them to interact intermolecularly [16],
and also seems to induce a conformational change in the
fibrin molecule [5, 17]. Polymerization proceeds using a half-
staggered molecular arrangement in which the knobs in the
central region of one fibrin molecule bind to holes in two
abutting, nearby molecules [18]. The central region of each
of those two molecules also contains knobs, which can bind
to two othermolecules, and so on. Polymerization propagates
in this manner, forming a double-stranded protofibril in the
process (see Figure 1(c)). Finally, to form fibers, protofib-
rils bundle together laterally through interactions between
the 𝛼C regions in adjacent protofibrils (see Figure 2) [5].
Fibers with truncated 𝛼C regions (A𝛼251) display thinner
fibers, lower stiffness, and enhanced fibrinolysis, emphasizing
the importance of this region of the fibrin molecule [19].
𝛼C domain interactions are thought to be mediated by
intermolecular 𝛽-sheet swapping of the 𝛽-hairpin region
[14] and produce high molecular weight digestion products
commonly called 𝛼-polymers that suggest many 𝛼C regions
link together in this manner. 𝛼-Polymers and the 𝛾-nodules
in protofibrils are further reinforced by Factor XIIIa (FXIIIa)
cross-linking, as discussed later in this report. The resulting
product is fibers ranging from eighty to several hundred
nanometers thick and 100’s of nanometers to 10’s of microm-
eters long [20, 21].
The nanostructure of fibrin fibers has been of longstand-
ing interest.Multiple experimentalmethods have determined
that fibers themselves also contain ∼80% water [22, 23], lead-
ing to estimates of pore sizes within fibers ranging from 1 to
30 nm [24, 25] and suggesting that fibrinolytic molecules can
diffuse even within a fiber [25–27]. Early EM studies on fibrin
showed a distinct 23 nm banding pattern across the diameter
of fibers, exactly half the length of the fibrin molecule
[28]. Later studies showed that protofibrils twist around the
exterior of fibers [20]. The banding patterns indicated a
lateral registry between protofibrils in the fiber, although
the interactions that cause the lateral registry were and still
are unclear. A model based on the crystal structures of fib-
rin(ogen) suggested a quasicrystalline packing of protofibrils
inside the fiber with unit cell of dimensions 19 nm x 19 nm ×
45 nm [29]. AFM and Small Angle X-ray Scattering (SAXS)
data suggested amodifiedmodel with a fractal fiber structure
still retaining quasicrystalline banding, but having larger
distances between protofibrils [23, 30]. Still other studies
suggest that the density of protofibrils is not uniform across
a fiber diameter and that the protofibril spacing increases as
a function of radial distance [20, 31]. Finally, other studies
emphasize the flexibility of protofibrils within fibers, which is
hard to reconcile with a quasicrystalline packing [32]. None
of the models currently include 𝛼-polymer networks into
the packing architecture. More work in this area could shed
light on fibrin mechanical properties and the mechanisms of
molecular diffusion during fibrinolysis.
Finally, it should be mentioned that while fibrinogen
is soluble, polymerized fibrin is insoluble. Thus, although
commonly used, Michaelis-Menten kinetics are not quite
correct in describing the action of an enzyme on an insoluble
substrate. Recent work on fractal kinetics has begun to
explore this issue [33].
2.2. Plasmin and tPA Binding Sites on Fibrin. Fibrinolytic
enzymes including plasminogen and tissue plasminogen
activator (tPA) bind to fibrin, and their binding sites will
be discussed here, although a detailed description of the
fibrinolytic molecules occurs in later sections of this review.
Of importance is the fact that fibrin, but not fibrinogen
enhances the activation of plasminogen by tPA [34], even
though sequence-wise fibrinogen and fibrin only differ by the
presence and absence fibrinopeptides A and B. Thus, it has
been hypothesized that the conversion of fibrinogen to fibrin
causes a conformational change, exposing binding sites for
plasminogen and tPA [18].
Intact fibrin has ∼100 lysine residues, but no C-terminal
lysines. Binding sites have been identified at the periphery
of the fibrin molecule for both tPA and plasminogen. The
𝛼 chain residues 148–160 bind both tPA and plasminogen
with equal affinity (KD ∼ 1 𝜇M) [35], and a monoclonal
antibody raised against the sequence was able to bind fibrin,
but not fibrinogen [36]. Electron microscopy studies of
plasminogen bound to fibrin also show that it binds to
the peripheral “D” region, in agreement with the antibody
epitope mapping (see Figure 2(a)) [37]. The binding is lysine
dependent, suggesting Kringle domain involvement [38]. A
lysine-independent tPA binding site has been localized to 𝛾
chain residues 312–324 that is also inaccessible to antibodies
in fibrinogen, but accessible in fibrin (see Figure 2(a)) [39].
The spatial localization of these sites is in agreement with the
observation that a ternary complex between fibrin, tPA, and
plasminogen is required to increase tPA’s catalytic efficiency
[37, 40].
Dysfibrinogenemias with abnormalities in the fibrin 𝛼C
region indicate further binding sites for plasminogen and
tPA [41, 42]. To test this, 𝛼C regions were recombinantly
expressed and binding to plasminogen and tPA was mea-
sured. Both enzymes bound with high affinity (16–33 nM)
[43] to lysine residues in the 𝛼C domain (𝛼392–610), and
binding was noncompetitive, suggesting different binding
sites for plasminogen and tPA. Other work indicates that the
tPA finger domain can bind to cross-beta structures in the
fibrin 𝛼C domain [44]. Thus, there may be multiple bindings
sites in the 𝛼C domain, but not the 𝛼C connector regions
(𝛼 221–391) for plasminogen and tPA. The 𝛼C region also
contains binding sites for FXIIIa (𝛼389–403) [45] and the
cross-linking site for 𝛼2-antiplasmin (𝛼2AP, L303) [46].
2.3. Degradation Products and C-Terminal Lysine Binding
Sites. At least 34 different plasmin cleavage sites have been
identified on fibrin(ogen), but different attack points are
cleaved at diverse rates. Because of this, plasmin leaves a series
of well-defined fibrin degradation products during lysis. The
lytic series was worked out in detail several decades ago
4 BioMed Research International
23 nm
Coiled coils unfold
-Nodules unfold
alphaC regions stretch
Plasmin cleavage site 
TPA/plasmin(ogen) binding site
TPA binding site
2AP binding site
(a)
(b)
(c)
(d)
(e)
(f)
Figure 2: Fibrin fiber structure andmechanical stretching. (a) Cartoonmodel of the fibrinmolecule showing fibrinolytic binding and cleavage
sites. Relative positions of plasmin cleavage sites, and tPA, plasmin(ogen), and𝛼2APbinding sites are color coded.Mechanical stretching alters
each site, as seen below. (b) A structural model for the fibrin fiber, consisting of protofibrils (c) linked together by unstructured 𝛼C regions.
Knob-hole interactions are not shown and the 𝛽- and 𝛾-nodules have been simplified to one structure in (b–f) for clarity. The protofibrils
align to give a 23 nm banding pattern as seen in electron microscopy images, although the interactions mediating this alignment are unclear.
The red dashes between adjacent molecules indicate the site of 𝛾-𝛾 FXIII cross-linking. (d–f) Cartoonmodels depicting extension of the fiber
arising from stretching of the coiled coil region (d), 𝛾-nodule (e), and the 𝛼C regions between protofibrils (f), respectively.
and has been reviewed elsewhere [47], so it will only be
mentioned briefly here.
The first attack point is A𝛼K583, which is partially
degraded even in circulating fibrinogen, and the cleavage of
which leaves a C-terminal lysine. Subsequent attack points
are 𝛼K206 and 𝛼K230, which remove nearly the entire 𝛼C
region of fibrin. This 𝛼C-less fibrin structure was historically
called fragment “X” (see Figure 1(a)); the detached 𝛼C region
is further degraded after removal.The next attack region is in
the coiled coil, where the 𝛼 (K78, K81, R95, R104, and R110), 𝛽
(K122, K133), and 𝛾 (K53, K58, K62, K85, and K88) chains all
contain 2–5 lysine and arginine residues known to be plasmin
cleavage sites. Transection of the coiled coil releases “the D
region” containing a portion of the coiled coil and the 𝛽-
and 𝛾-nodules (see Figure 1(a)). Upon the cleavage of the
other coiled coil, “the E region” is produced, which includes
the central region of the molecule containing the N-terminal
disulfide knot and a portion of the coiled coil. In FXIIIa
ligated fibrin, the D region is covalently cross-linked to an
adjacent molecule, and “D-D” and “D-E-D” (where a D-D is
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noncovalently bound to region E via knob-hole interactions)
fragments are released.
The creation of C-terminal lysines in partially degraded
fibrin serves as a feedback mechanism for more plasminogen
and tPA binding. tPA binding to degraded fibrin is 2–4 orders
of magnitude tighter than binding to intact fibrin [48]. Also,
removal of the 𝛼C region eliminates the protection of 𝛼2-
antiplasmin (𝛼2AP) from the immediate vicinity of the fibrin
molecule, potentially increasing fibrinolysis further.
3. Fibrinolytic Agents:
Activation and Inhibition
3.1. Plasminogen and Plasmin Structure, Conformation, and
Function. The primary fibrinolytic agent is the serine pro-
tease plasmin. It is a trypsin-like enzyme with broad speci-
ficity that cleaves peptide bonds at the C-terminal side of
lysine and arginine residues. Plasmin is the activated form
of the zymogen plasminogen, which circulates as a single
791 amino acid chain at concentrations of ∼2 𝜇M [49].
Several structural features regulate the binding and activity
of plasmin(ogen) [the nomenclature plasmin(ogen) will refer
to features common to both plasmin and plasminogen].
Plasmin(ogen) has historically been subcategorized,
based upon its glycosylation state, into Type I and Type II.
Type I has anN-linked glycan atN289 and anO-linked glycan
at T346 and comprises 40% of circulating material [50, 51].
Type II only has the O-linked T346 glycan and comprises
60% of circulating material. Subsequent studies suggested
that some Type II plasminogen could contain a second O-
linked glycan at S248 [52] or S339 [53]. Glycosylation plays a
dramatic role in regulating the binding of plasmin(ogen) to
particular cell types [54] and seems to play a minor role in
the activation of plasminogen on fibrin [55].
The crystal structure of plasminogen was recently deter-
mined shedding further light on the structural determinants
of plasmin(ogen) function [56, 57]. It can be structurally
segregated into an N-terminal Pan-apple domain (PAp;
∼1–77), 5-Kringle domains (Kr-1, Kr-2, Kr-3, Kr-4, Kr-5;
∼78–542), and a serine protease domain (562–791) [56, 58].
Kringle domains 1, 2, 4, and 5 contain a DXD/E motif for
binding C-terminal lysine residues, and lysine binding seems
to be the primary mechanism for plasmin(ogen) binding
to fibrin and/or cell-surface ligands [58, 59]. In Kringle 3,
the motif has been mutated to DXK, and lysine binding
is abolished [60]. In the closed conformation (discussed
below), only Kr-1 is exposed for binding, suggesting that this
domain mediates the initial recruitment of plasmin(ogen) to
its binding partners [56, 57].
The PAp domain (sometimes called the N-terminal pep-
tide [57] or activation peptide [58]) plays an important role
in regulating plasmin activity and activation. With the PAp
attached, plasmin(ogen) (referred to as Glu-plasmin(ogen),
in this case) is predominantly found in a compact confor-
mation mediated by an interaction between the PAp and
Kr-4/Kr-5 [56, 57]. The compact conformation (typically
called the closed conformation) has rough dimensions of
9 nm × 6 nm [37, 57] and a radius of gyration of 3.1 [61] to
3.9 nm [62]. However, plasmin(ogen) can also adopt a much
larger U-shaped conformation (the open conformation) with
rough dimensions of 14 nm × 7 nm [37] and a radius of
gyration of 5.0 [61] to 5.6 nm [62]. Natively there is some
thermal equilibriumbetween the two conformations [63], but
the open conformation can be stabilized either through the
cleavage of the PAp by plasmin at residue Lys77 or by the
binding of lysine or lysine-analogs to the Kr-4/Kr-5 domains.
Upon cleavage of the PAp domain, plasmin(ogen) is referred
to as Lys-plasmin(ogen). Interestingly, Lys77 is buried in
the closed conformation and inaccessible to plasmin, so
some conformational rearrangementmust occur prior to PAp
cleavage [56].
Plasminogen activators cleave the bond between R560
and V561 in the C-terminal region of plasminogen [64],
exposing the catalytic triad H603, Asp646, and Ser741 in
the serine protease domain. This is the crucial step in the
conversion of plasminogen to plasmin and results in a
double-stranded plasminmoleculewhose two chains are held
together by disulfide bonds [65]. The plasmin light chain
(∼25 kDa) contains the catalytic site, while the heavy chain
(∼60 kDa) contains the Kringle domains. The R560-V561
bond is shielded from proteolysis by both the Kr-3/Kr-4 loop
and the T346 O-linked glycan in the closed conformation
of plasminogen [56]. However, the open conformation has
a 3–50 fold increased rate of activation [63], suggesting that
R560-V561 shielding is greatly reduced in this conformation.
Thus, there is a direct connection between the confor-
mation of the plasminogen molecule and its ability to be
activated to plasmin. Because the plasminogen conformation
is governed by the interaction between PAp and Kr-4/Kr-
5, cleaving the PAp domain or plasminogen binding to C-
terminal lysines, as is the case when binding to fibrin or cell
receptors, will greatly enhance the conversion to plasmin.
Additionally, because Glu-plasminogen can bind to ligands
prior to PAp cleavage, and binding promotes activation,
it is possible to have Glu-plasmin, in addition to Glu-
plasminogen. However, higher local plasmin concentrations
lead to higher catalytic rates of PAp cleavage, so the pre-
dominant activation pathway is Glu-plasminogen → Lys-
plasminogen→ Lys-plasmin.
3.2. Plasminogen Activators (PA’s). The two primary phys-
iological plasminogen activators are the serine proteases
urokinase-type plasminogen activator (uPA) and tissue-type
plasminogen activator (tPA) (for more detailed reviews see
[65–68]). While having similar catalytic function, differences
in the binding domains of uPA and tPA result in differen-
tiation in localization and different biological roles for the
two PA’s [66]. Other potential physiological plasminogen
activation pathways, such as the contact activation pathway
will not be covered in this review [68, 69].
3.2.1. uPA. uPA is secreted as a single-chain, 411-amino
acid, protein (sc-uPA) that has very little intrinsic catalytic
activity in plasma [70, 71]. uPA activation transpires from
the proteolysis of L158-I159 bond, converting sc-uPA to two-
chain uPA (tc-uPA) and exposing the serine protease site
[72]. tc-uPA also has a low molecular weight form, created
via plasmin cleavage of the L135-L136 bond [69, 73], which
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circulates in plasma, but most circulating sc-uPA and tc-uPA
are cleared from plasma within minutes [74].
uPA consists of three structural regions, a C-terminal
serine protease domain (159–411), a Kringle domain (50–132),
and a growth factor domain (GFD; 10–43) [75]. Unlike tPA,
uPA’s Kringle domain does not have a fibrin binding site,
and uPA has low affinity for fibrin [69]. uPA binds tightly
(KD < 1 nm) [76] to cell-surface receptor urokinase-type
plasminogen activator receptor (uPAR) through its GFD [77,
78], although it also binds and activates plasminogen on
platelets, which do not express uPAR [79]. Interestingly, sc-
uPA shows ∼100 fold increase in activity when bound to cell
surfaces, while tc-uPA’s activity is not increased further by cell
binding [79, 80].
uPA primarily activates cell-surface bound plasminogen,
although it can also activate solution-phase plasminogen,
in contrast to tPA [68]. Surface-activated plasmin plays
an important role in extracellular matrix degradation and
growth factor activation [81]. The precise role uPA plays
in fibrinolysis is still controversial; however, mouse models
show an active role for uPA in fibrinolysis [82, 83] and tc-
uPA activates Glu-plasminogen at a 10-fold higher rate in the
presence of fibrin in spite of not binding to fibrin [69], so uPA’s
role in fibrinolysis should not be minimized.
3.2.2. tPA. tPA is synthesized and secreted by endothelial
cells as a single-chain, 527-amino acid, glycoprotein. The
plasma concentration of tPA is 70 pM, and it has a half-
life of 4 minutes, so it is tightly regulated [68, 84]. Unlike
other serine proteases like uPA and plasmin, the single
chain of tPA (sc-tPA) has inherent catalytic activity and can
activate plasminogen [85]; however, cleavage of the R275-
I276 bond by plasmin and conversion to two-chain tPA (tc-
tPA) increases plasminogen activation rates from 3- to 10-fold
in the absence of fibrin [34, 40]. In the presence of fibrin, the
activity of tPA is increased from 100- to 1000-fold and sc-tPA
and tc-tPA have comparable catalytic rates [34, 40, 86]; the
presence of fibrinogen does not increase tPA activity [18, 40].
There is strong evidence that the rate enhancement occurs
due to the formation of a ternary complex between fibrin,
plasminogen, and tPA [37, 40].
Fibrin stimulation of plasminogen activation by tPA
occurs in two phases [87–89]. The first phase is mediated by
the conversion of fibrinogen to fibrin and the exposure of
cryptic tPA and plasminogen binding sites on fibrin. During
this phase the typical tPAKm value is∼1 𝜇Mplasminogen and
the catalytic rate constant is ∼0.2 s−1 [40, 89]. Upon plasmin
formation, COOH-terminal lysines become exposed as fibrin
is digested; this provides more binding sites for plasminogen
and tPA and creates a positive feedbackmechanism, resulting
in Km values for tPA ∼ 100 nM plasminogen while retaining
the same catalytic rate constant [89]. For these reasons, tPA is
thought to be the predominant plasminogen activator during
fibrinolysis.
Structurally tPA consists of 5 distinct domains: a fin-
ger domain, an epidermal growth-factor-like domain, two
Kringle domains, and the catalytic domain [90]. The finger
domain and the Kringle-2 domain serve as the primary fibrin
binding sites [86]. The Kringle-2 domain plays a role in C-
terminal lysine binding, while the finger domain can bind
to a region in the fibrin 𝛾-nodule in a lysine-independent
mechanism [91] or to amyloid-like cross-beta structures [44],
which have been hypothesized to form in fibrin 𝛼-polymers
[14, 92]. Recent work has shown that the tPA finger domain
plays the predominant role in binding to fibrin during
fibrinolysis [93, 94], even in proteolytically degraded fibrin.
Fibrin thus acts as both a cofactor and substrate for tPA
and plasminogen and in so doing provides themechanism for
its owndisintegration.These dual roles highlight the intended
temporariness of the fibrin mesh network; it is not designed
to stick around for longer than is necessary for wound healing
in most physiological circumstances.
3.3. Fibrinolytic Inhibitors. The proteases of the fibrinolytic
system are all tightly controlled by inhibitors. For recent,
thorough reviews, the reader is directed to [68, 95]. For the
purposes of this review, they will only be covered briefly.
3.3.1. 𝛼2-Antiplasmin (𝛼2AP). 𝛼2AP serves as the fast-acting
(4 × 107M−1s−1) [96] primary inhibitor of plasmin and
circulates in plasma at concentrations of ∼1 𝜇M, usually in
excess of plasmin, with a half-life of 3 days [68, 97]. 𝛼2AP
is also cross-linked to fibrin by FXIIIa, so there is a high local
concentration in clots (this is described in more detail later
in this review) [98], and there are additional noncovalent
𝛼2AP binding sites in fibrin, but not fibrinogen [99]. Like
other serpin inhibitors, 𝛼2AP inhibits plasmin by inserting
a “reactive center loop (RCL)” into plasmin’s catalytic site,
which then attacks the R364-M365 peptide bond of the
loop [100]. This releases the N-terminal portion of 𝛼2AP,
while forming a covalent ester-bond between 𝛼2AP and the
catalytic site, inhibiting plasmin. The lysine-rich C-terminus
of 𝛼2AP is ∼55 residues longer than most serpins and
contains a binding site for plasmin(ogen) Kringle domains
[97, 101]. Plasminogen-fibrin and plasminogen-𝛼2AP bind-
ing are competitive; plasmin activated while bound to fibrin
is therefore relatively protected from 𝛼2AP, although the
unbound 𝛼2AP can still inhibit plasmin albeit at a 100-fold
slower rate [100].
3.3.2. Plasminogen Activator Inhibitors 1, 2 (PAI-1 and PAI-2).
PAI-1 is the physiological inhibitor of both uPA and tPA. Like
𝛼2AP, PAI-1 is a serpin inhibitor, with its reactive site at R346-
M347 [95]. PAI-1 inhibits both tPA and tc-uPA with second-
order rate constants of roughly 1−4 × 107M−1s−1 [102, 103].
Activated platelets can release PAI-1 and increase its local
concentration 10-fold [104], helping to reduce fibrinolysis at
the onset of clotting.
PAI-2 also is a serine protease that inhibits tPA (1 ×
104M−1s−1) and uPA (2 × 106M−1s−1), but with slower rate
constants than PAI-2 [105]. Its primary function may be
related to placental maintenance rather than fibrinolysis, as
it is only present in plasma during pregnancy [68, 95].
3.3.3. Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
TAFIa is not a serine protease and has an entirely different
mechanism than other fibrinolytic inhibitors [106]. TAFIa
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is produced from its zymogen TAFI by cleavage at R92-
A93 by the thrombin/thrombomodulin complex [107]. TAFIa
removes C-terminal lysine and arginine residues from fibrin
as it is degraded, preventing plasminogen binding and the
positive feedback mechanisms that stimulate lysis [108]. It
also prevents the conversion of Glu- to Lys-plasminogen,
reducing the rate of plasminogen activation [109]. Thus,
TAFIa does not directly inhibit lysis, but rather slows down
several crucial steps in fibrinolytic upregulation.
4. Biophysical Determinants of Fibrinolysis
4.1. Clot Structure and Architecture. Blood clot content and
architecture help to determine their lytic susceptibility. Fibrin
network structure is determined by the local concentrations
of fibrinogen, thrombin, and ions, such as Ca2+ [110, 111].
High fibrinogen concentrations, such as those experienced
in hyperfibrinogenemia, high local thrombin concentrations,
and high plasma ionic strength give rise to clots with thinner
fibers at a higher density (less space between fibers) [110–113].
Conversely, increasing the Ca2+ concentration or decreasing
the thrombin concentration leads to clots composed of
thicker fibers and a lower packing density [110]. A long history
of rheological studies suggest that clots composed of thin,
densely packed fibers are stiffer than those of thick fibers with
larger pore sizes [110, 114, 115].
The mechanism by which individual fibers are lysed has
been a subject of debate. Several studies, primarily using
turbidity as a readout of fibrinolysis, and models suggested
that the diameter of fibrin fibers decreases uniformly during
lysis due to many plasmin molecules binding and digesting
the fiber along its entire length [116–118]. It should be
noted that using turbidity to measure lytic rates has been
a subject of controversy with respect to whether the data
should be normalized by the highest turbidity value [119];
doing the normalization lowers the apparent lytic rates after
polymerization reaches its maximum but ignores digestion
prior to that point. Other studies, primarily using fluorescent
and electron microscopy reported transverse cleavage of
fibers at one point [120–123]. Because C-terminal lysines
are exposed during lysis, plasminogen binding to partially
degraded fibrin will be amplified at points where fibrin has
already been cleaved [124]. It has been hypothesized that this
serves as a feedback mechanism to promote further lysis at
those points, leading to transverse cleavage directly across
the diameter of the fiber [26]. Studies of individual fiber lysis
showed that cleavage does occur at a specific point but also
that the lytic rate for further fiber degradation slows after
the initial transverse cleavage event [121]. It is often observed
that cleaved fibers bundle together to form thicker fibers
[120, 123] prior to being degraded further. It is likely that both
transverse cleavage and digestion along the fiber length play
a role during fibrinolysis, perhaps with transverse cleavage
mediating the initial digestive event.
The conventional wisdom has been that fiber density
(the number of fibers per unit volume) and fiber thickness
have competing effects on fibrinolysis. Numerous in vitro
studies have reported that clots composed of thinner, more
closely spaced fibers, are more resistant to fibrinolysis [111,
112, 120, 125]; however, several studies have shown an opposite
effect, so this is not necessarily always the case [116, 126].
Hypofibrinolysis has been reported for patients with thin,
dense fibers, supporting the idea that clots composed of
thinner fibers aremore resistant to lysis [127, 128]. Conversely,
thin fibers were more rapidly cleaved than thick fibers in
a variety of fibrinolysis models [120, 121, 123, 126]. These
contrasting results likely come from the interplay between
the movement of fibrinolytic agents (plasminogen, plasmin,
tPA, etc.) within a clot, and the activity of those agents
on fibers upon binding. It is important to note that, in
most in vitro studies of fibrinolysis, plasmin or plasminogen
activators such as tPA or uPA are added from outside an
already formed fibrin network. Therefore, the permeation of
fibrinolytic agents into a clot plays a predominant role in
determining clot lysis rates. These studies are important for
the development of therapeutics that must be administered
from outside the clot but may not mimic in vivo fibrinolysis
which happens concurrently with polymerization [123].
In the case where lytic agents are released from outside
the clot, recent 3D stochastic modeling suggests that the
determining factor in fibrinolytic rates is the number of tPA
molecules per clot surface area [27]. Bannish et al. found that,
for low tPA concentrations, clots of thick fibers lyse more
rapidly, but for higher concentrations (high enough for at
least one tPA molecule to bind to every fiber on the surface
of the clot), clots composed of thinner fibers will actually lyse
faster than those of thick fibers [27].These results may help to
explain the discrepancies between previous experiments and
suggest avenues for therapeutic development.
The observation that thicker fibers lyse more slowly has
been explained, in part, by several phenomena. First, thin
fibers are composed of fewer protofibrils within a cross-
section, so fewer molecules need to be cleaved in order to
transect a fiber [26, 27]. Also, within thin fibers themolecules
are more densely packed, so plasmin and tPA binding sites
are closer together [31], and it has been observed that thin
fibers are better for plasminogen activation by tPA [93].
Therefore, all other things being equal, thin fibers should
lyse more rapidly than thick fibers. Secondly, thicker fibers
are likely under more tension than thinner fibers due to
protofibril packing [20]. Modeling and experiments show
that, as fibers are lysed, they lose this inherent tension
leading to elongation, and elongation hinders fiber lysis [121].
Elongation is more prominent in thicker fibers than thin
fibers providing additional reasons that thin fibers lyse more
rapidly. Finally, models predict that the amount of time tPA
remains bound to fibers can have a noticeable influence on
lytic rates of individual fibers, and tPA remains bound longer
to thicker fibers than thin ones independent of the tPA off-
rate, if the off-rate is sufficiently slow [27].
4.2. FXIIIa Cross-Linking. The transglutaminase FXIIIa likely
regulates fibrinolysis through at least three distinct mech-
anisms: (1) cross-linking fibrinolytic inhibitors, particularly
𝛼2-antiplasmin, to fibrin, (2) cross-linking fibrin fibers, and
(3) altering the mechanical properties of fibers and fibrin
networks.
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FXIII is a protransglutaminase consisting of two A and B
subunits (A
2
B
2
) in plasma and as a homodimer of A subunits
(A
2
) in cells [129]. Plasma FXIII is activated in the final step of
the clotting cascade when thrombin hydrolyzes the R37-G38
bond, releasing an activation peptide, and Ca2+ causes the
dissociation of the B subunit, resulting in a catalytically active
A
2
dimer usually referred to as FXIIIa. The rate of plasma
FXIIIa activation is accelerated 6-fold in the presence of
polymerized fibrin [130]. Cellular FXIII, such as that released
by platelets and monocytes, is activated in a thrombin- and
fibrin-independent mechanism involving Ca2+, where the
activation peptide is not removed [131].
It now seems clear that cross-linking 𝛼2-antiplasmin
(𝛼2AP) to fibrin is the primary antifibrinolytic function of
FXIIIa [98, 132]. 𝛼2AP plays several inhibitory roles in fibri-
nolysis including rapidly inhibiting plasmin and interfering
with the binding of plasminogen to fibrin lysine sites [46,
133]. During fibrin polymerization, FXIIIa covalently cross-
links 𝛼2AP via its Q2 residue to L303 in the fibrin 𝛼C
linker region [46, 134]. 𝛼2AP cross-linking precedes 𝛼 chain
cross-linking by FXIIIa (see next paragraph) and may inhibit
this process [129, 133]. Uncross-linked 𝛼2AP has similar
plasmin inhibitor activity to cross-linked 𝛼2AP, but cross-
linked 𝛼2AP has a much greater effect on the inhibition of
lysis [135]. This inhibitory effect is increased during platelet
retraction, when the fibers of the clot are closer together
and fluid is expelled from the clot [132, 135]. FXIIIa can
also cross-link other fibrinolytic inhibitors to fibrin(ogen),
including PAI-2 [136] and TAFI [137]. These results strongly
support the hypothesis that FXIIIa inhibits fibrinolysis by
the covalent incorporation of fibrinolytic inhibitors into the
fibrin network. This may be particularly important dur-
ing the early stages of clot formation, protecting against
immediate elimination of nascent clots [129]. However,
other studies have shown that 𝛼2-antiplasmin works in
concert with 𝛼 chain cross-linking in fibrinolytic inhibition
[138], so FXIIIa cross-linking of fibrin itself likely also has
inhibitory effects.
During fibrin polymerization, FXIIIa forms 𝛾-glutamyl-
𝜀-lysyl cross-links between residues in the 𝛾 and 𝛼 chains
of fibrin monomers. FXIIIa first catalyzes the formation of
isopeptide bonds between 𝛾1L406 and 𝛾2Q398 or 𝛾2Q399
at the C-terminal 𝛾-nodules of adjacent molecules, form-
ing longitudinal 𝛾–𝛾 dimers within protofibrils [139]. Later
during polymerization, FXIIIa targets lysine and glutamine
residues in the 𝛼C region, resulting in the formation of high
molecular weight fibrin species including 𝛼-polymers and 𝛼-
𝛾 hybrids [140–142]. Although there is no set order in which
𝛼 chain glutamine residues are cross-linked, generally Q237
is targeted first, followed by Q366, Q328, and Q221 [143].The
𝛼 chain lysine donors are more heterogeneous but involve at
least L418, L508, L539, L556, L580, and L601, most of which
are located at theC-terminal periphery of the𝛼C region [144–
146]. FXIIIa cross-linking causes slight, but not dramatic
changes in networkmorphology, with 10% thinner fibers, and
a 2-fold reduction in pore size [110, 147].
Whether FXIIIa cross-linking effects fibrinolytic rates
was a subject of historical [148–150] and even recent [98, 147]
debate, complicated by sample preparation and the pres-
ence of fibrinolytic inhibitors. A recent study, where 𝛼2-
antiplasmin was inhibited, established that FXIIIa cross-
linked fibers have delayed fibrinolysis, even in the absence
of external mechanical force [147]. These results agreed
with previous studies showing decreased lysis by plasmin
on FXIIIa ligated clots [151]. This may be due, in part, to
the decreased binding affinity of plasmin or plasminogen
to cross-linked fibers [126, 129]. Some studies show that
specifically 𝛼 chain cross-linking plays an important role
in reducing the fibrinolytic susceptibility of clots [140, 149],
although there is not universal agreement [147, 148]; it seems
feasible because 𝛼 chain cross-linking likely reduces the
number of lysines available for plasminogen and tPA binding,
decreases the mobility of molecules between protofibrils
[129], and makes protofibril packing more dense [152]. Other
studies have shown a predominant role for 𝛾-cross-linking
and even 𝛾-multimers in regulating fibrinolytic rates [153].
In summary, it seems that cross-linking of fibers plays a
measurable, but potentially minor role in fibrinolysis.
FXIIIa cross-linking has a dramatic effect on fibrin
mechanical properties. Uncross-linked or partially cross-
linked (some low molecular weight species) fibrin fibers are
among the most extensible biomaterials found in nature, able
to be stretched to triple or quadruple their original length
before failing and also able to relax back to their original
length within milliseconds [1, 15, 154, 155]. Fully cross-linked
fibers (>90% 𝛾 and 𝛼 chains cross-linked) are 2–10 times
stiffer, 50% less elastic, and have 40–50% lower extensibility
than partially cross-linked fibers [21, 155]. Studies using
recombinant fibrin with 𝛾 chain cross-linking sites mutated
out (𝛾Q398N/Q399N/K406R) reveal that loss of fiber elastic-
ity and extensibility is primarily due to 𝛼 chain cross-linking
[156]. Loss of fiber extensibility may explain the recent obser-
vation that during clot retraction erythrocytes are trapped in
FXIIIa cross-linked fibrin networks without being covalently
bound to the fibers [157, 158], while erythrocytes in uncross-
linked fibers were extruded.
Fibrin networks also have remarkable extensibility, due
in large part to the mechanical properties of their individual
fibers [2, 32]. In rheological studies, where network mechan-
ical properties typically depend more on fiber structural
rigidity and network rearrangement than fiber stretching,
networks composed of cross-linked fibers also exhibited a 2-
to 5-fold higher elasticmodulus (stiffness) and a 2-fold higher
loss modulus [21, 141, 152, 159]. Rheological measurements
on (𝛾Q398N/Q399N/K406R) fibrin suggest that FXIIIa-
mediated stiffening comes from contributions of 𝛼- and 𝛾-
cross-linking, with 𝛼 chain cross-linking playing the largest
role [141]; other studies demonstrate that the mechanism of
network stiffening comes from FXIIIa-mediated structural
rigidity increases of individual fibers [152].
The effect of different mechanical properties in FXIIIa-
cross-linked fibrin on fibrinolytic rates has not been directly
explored, but several mechanisms can be proposed. First, the
reduced extensibility of FXIIIa cross-linked fibers limits the
extension of fibers during platelet retraction. Platelets carry
endogenous FXIIIa, so most fibers are highly cross-linked
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during retraction, and because retraction plays multiple roles
in regulating fibrinolysis (discussed below), it is likely that
the increased stiffness of FXIIIa fibers has a mechanism in
this regulation. Second, Varju´ et al. showed that fiber stretch-
ing decreased plasminogen activation and lysis, suggesting
that stretching of fibrin alone regulates fibrinolysis [3], and
thus reduced extensibility of fibrin by FXIIIa should affect
fibrinolytic rates via this mechanism as well. Third, under
certain conditions, thick fibers elongate during lysis and reach
a lysis resistant state [121]. FXIIIa cross-linking could alter
the elongation and lytic resistance of these fibers. While only
hypotheses at this point, these ideas highlight the need for
further studies to measure the direct effect of altered fibrin
mechanical properties on the fibrinolytic susceptibilities of
fibrin clots.
Recently it was shown that plasmin can inactivate FXIIIa,
by cleaving the enzyme at a variety of sites, predominantly
the K468-Q469 bond [160]; contrastingly, FXIII (A
2
B
2
) was
not degraded in the same manner. FXIIIa inactivation by
plasmin occurs primarily during fibrinolysis rather than
polymerization suggesting it serves as a feedback mechanism
to prevent further FXIIIa activity after the cessation of
clotting. This could also avert the further incorporation
of fibrinolytic inhibitors such as 𝛼2AP into the clot, thus
promoting fibrinolysis.
4.3. Movement of Fibrinolytics into and within Fibrin Net-
works. The transport of fibrinolytic agents into a clot and
their movement within a clot depend on diffusion (the
randommovement ofmolecules due to thermal fluctuations),
advection (the conveyance of particles within flowing fluid;
sometimes referred to as convective transport, permeation,
or perfusion), and binding (to fibrin or other clot constituents
like platelets or erythrocytes). Fibrinolytic transport has been
covered in other reviews [24, 161]; the physical aspects of this
process will be reviewed here.
Penetration of fibrinolytics into blood clots depends on
the network architecture and contents. Networks formed of
purified fibrin have a fibrin content usually <1% of the total
network volume at physiological fibrinogen concentrations
[161]. Under these conditions, the average pore size (space
between fibers) ranges from 100 nm in gelsmade of thin fibers
to 10 𝜇m in gels made of thick fibers [24]. The diffusion of
a molecule such as plasmin(ogen), with a stokes radius of
∼5 nm, within the pores between fibers and cells can roughly
be thought of as free diffusion [24, 161].
Cells, such as erythrocytes and platelets, modulate net-
work structure through direct fibrin-cell receptor binding
and the release of pro- and anticoagulation factors [162,
163]. Moreover, tissue-factor bearing cells promote fibrin
production and can lead to high local fibrin concentrations
during polymerization [125]. High local fibrin concentration
(up to 400 𝜇M) could decrease the fiber pore size to as
low as 4 nm [164], but this is likely not the case under
most physiological situations. Even for platelet retracted clots,
where 99% of the fluid volume has been expelled, the porosity
is still >90% [24]. Taken together, these data suggest that
undermost conditions, the diffusion of fibrinolyticmolecules
into and within a clot should roughly mimic free diffusion
[165]; however, a recent report on fibrinolysis of stretched
fibrin clots reported hindered diffusion into the clot based on
Fluorescence Recovery after Photobleaching (FRAP), so this
might not always be the case [166].
Although network structure usually does not hinder
diffusion, the binding of fibrinolytic molecules to fibrin or
cellular constituents plays a dramatic role in reducing their
mobility [24, 27, 161]. Fluorescent microscopy studies on
the lysis of clots initiated by adding lytic agents outside the
clot often show a “lysis front” where plasmin, plasminogen,
or tPA bind to the first few microns of a clot without
penetratingmuch further [120, 124].The network is dissolved
progressively from outside to inside as the lysis progresses.
Streptokinase, which does not bind tightly to fibrin, pene-
trates clots more rapidly than tPA [167], and studies using a
tPA variant defective in fibrin binding also observed more
rapid penetration into clots [93]. Networks composed of
thin, densely packed fibers, have more binding sites per unit
volume for plasminogen and tPA, which helps to explain the
hindered fibrinolysis for these types of clots [27, 120].
Molecular penetration into clots and fibrinolysis rates
can be enhanced from 10- to 100-fold by the presence of
flow and molecular advection [118, 168, 169]. Flow allows
fibrinolytics to travel further into a clot prior to binding,
enhancing the inner-clot fibrinolytic rate. The direction of
flowmatters as tangential flowwith respect to the clot can lead
to a “plasmin steal” effect where flow depletes plasminogen
from the clot boundary [124]. However, a study on retracted
blood clot dissolution under tangential flow still showed a
10-fold increase in clot degradation [170]. In the case of flow
directly into a thrombus, the fluid will flow through the least-
permeation-resistant path, so structural heterogeneity can
have dramatic effects on the delivery of fibrinolytics [118, 169].
As the fibrin network is digested, channels will be carved out,
and further digestion will emanate outward from the channel
[124, 171]. In the case of a completely occluded blood vessel,
once a channel is carved through a thrombus, reperfusion of
the channel is achieved. The accompanying drop in pressure
can reduce the transport of further fibrinolytics into the
clot due to flow, and further lysis must proceed through
diffusion and binding, as described above. The difference
in transport in arterial and venous flow rates can have a
dramatic difference in the impact of advection on fibrinolytic
rates [161], and therapeutic strategies should be designed
accordingly.
4.4. Fiber Stress and Extension. Fibrin is among the most
extensible biomaterials [1, 172]. Fibrin’s elasticity and exten-
sibility may play prominent roles during blood clot for-
mation under shear stress [3, 173–175] and during platelet
retraction [176, 177]. The molecular mechanisms underlying
fibrin extensibility have recently been debated (see Figures
2(d)–2(f)) [178]. Fiber extension measurements, simulations,
and a comparison of human, mouse, and chicken fibrin
extensibilities all suggest that the 𝛼C connector region plays
a large role in fibrin elasticity [32, 154, 156, 179, 180]. Other
measurements and simulations suggest that unfolding of
either the coiled coil region [2, 181–183] or the 𝛾-nodule could
play roles [15, 182, 184]. Because plasmin(ogen) has potential
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Figure 3: Interaction network of the biophysical determinants of fibrinolysis rates. A diagram highlighting the influence of FXIIIa, network
architecture, platelets, and fluid flow on lytic rates. The diagram is simplified and does not include many of the interactions discussed in the
paper but is meant to emphasize some of the major impacts. Black arrows show an influence of one property on a downstream property.
The end result is either faster or slower network fibrinolytic rates. The red arrow indicates that cross-linked fibrin fibers have reduced
extensibility and thus reduced fiber stretching. “Fibrinolytic activation/increased binding” and similarly worded effects are meant to indicate
that a fibrinolytic enzyme such as plasmin is activated and/or has increased binding affinity or avidity.
binding and cleavage sites in each of these regions, fibrin
stretching could act as a modulator for fibrinolysis.
During clot retraction (contraction) fibrin fibers are
stretched by platelets. This reduces the interstitial spacing
between fibers, reduces clot volume, and expels up to 99%
of the liquid from within the clot [185]. Retraction may
also help to segregate red blood cells (erythrocytes) and
form a more effective wound seal [186]. For many years,
it has been observed that lysis is altered by clot retraction,
and the consensus of most in vitro studies is that platelet
retraction inhibits fibrinolysis [185, 187–191]; however, the
effects and mechanisms have been debated. One proposal is
that the expulsion of unboundplasminogen during retraction
reduces lytic rates [185, 192, 193]. tPA binding to fibrin
also is inhibited by retraction and may play a larger role
than plasminogen depletion in hindering fibrinolysis [189,
191]. Other studies suggested that the increased concentra-
tion of FXIIIa-cross-linked 𝛼2-antiplasmin in retracted clots
resulted in higher plasmin deactivation and slower lysis [132,
194, 195]. Studies on the effects clot retraction on fibrinolysis
are complicated by the fact that activated platelets contain
and/or release a number of hemostatic and fibrinolytic fac-
tors including fibrinogen, FXIIIa, plasminogen, plasminogen
activators, 𝛼2AP, and PAI-1, so it is likely that platelets
and retraction have multiple roles in regulating fibrinolysis
[190, 194, 196, 197].
Several studies have looked at the direct impact of fibrin
strain on lysis rates. A study by Varju´ et al. attempted to
directly measure the fibrinolysis of stretched networks of
fibers in the absence of platelets and found that the digestion
of fibers formed under mechanical stress was delayed [3].
Plasminogen activation by tPA decreased by 2- to 3-fold on
stretched fibers as compared to unstretched. The digestion of
stretched surface fibers by both tPA activated plasminogen,
and by the direct addition of plasmin, showed a greater
than 50% reduction in lysis at comparable time points when
compared to unstretched fibers. Another study by Adhikari
et al. found a 10-fold reduction in plasmin degradation of
strained clots and correlated this with a reduction of diffusive
transport into the network [166]. These results suggest that
fiber stretching impairs fibrinolysis by delaying plasminogen
activation, reducing the fibrinolytic ability of plasmin, and
hindering the entrance of fibrinolytics into the network.
In contrast, a study on the lysis of individual, isolated,
unstretched fibrin fibers by plasmin showed that as fibers
are lysed, they lose their inherent tension and elongate [121].
Elongated fibers reached a state where further fibrinolysis
was impaired and often were not further digested. The effect
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was dependent on fiber diameter, with thicker fibers more
likely to elongate, but independent of plasmin concentration.
The results suggested that a minimum fiber tension may
promote plasmin activity [121]. Because fibrin fibers form
under tension [20, 198], one resolution is that polymerization
tension is required for fibrinolysis, but the addition of
external tension, such as in the case of retraction, hinders
fibrinolysis.
Taken together, these results suggest that fiber tension
and stretching play an important role in the regulation of
fibrinolysis, altering the binding of plasminogen activators,
the availability of fibrinolytic enzymes, and the activity of
plasmin. Models of fibrin extension often rely on protein
unfolding to correlate extensibility with molecular structure
[2, 184]. Unfolding of the coiled coil or 𝛾-nodule or stretching
of 𝛼C domains [154] could alter or partially block enzyme
binding and cleavage sites. Further studies could help to
decouple the roles between these different effects.
5. Conclusions
Coagulation and fibrinolysis are very physical processes,
performed amid fluid flow, cellular adhesion, and platelet
contraction. This review has highlighted several biophysical
mechanisms that regulate fibrinolytic rates (see Figure 3).
Additional work in this area is needed to understand the
mechanisms undergirding the delayed lytic rates of strained
fibrin, given that platelet retracted clots contain almost
exclusively stretched fibrin fibers. Improved understanding
of the connection between the biophysical aspects of fibrin
and fibrinolytic rates could lead to new strategies in the
development of future fibrinolytic therapies [199].
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